Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Centre Oscar Lambret
Tesaro, Inc.
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AstraZeneca
National Cancer Center, Korea
Impact Therapeutics, Inc.
Amgen
AstraZeneca
AstraZeneca
Gilead Sciences
NRG Oncology
Merck Sharp & Dohme LLC
Tesaro, Inc.
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
EMD Serono
ARCAGY/ GINECO GROUP
National Cancer Institute (NCI)
Akeso
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
London School of Hygiene and Tropical Medicine
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
Xiamen University
The Netherlands Cancer Institute
Pfizer
pharmaand GmbH
Merck Sharp & Dohme LLC
UNICANCER
Corcept Therapeutics
Shanghai Gynecologic Oncology Group
AstraZeneca
Karyopharm Therapeutics Inc
University College, London
Huazhong University of Science and Technology
Cordgenics, LLC
Akeso
Huazhong University of Science and Technology
Karolinska Institutet
Leiden University Medical Center
Beijing Health Guard Biotechnology, Inc